Albuminuria and cardiovascular risk: Basal results of the koral-cardio study;Albuminuria y riesgo cardiovascular. Estudio KORAL-CARDIO

Nefrologia

Volumn 26, Issue 4, 2006, Pages 426-432

  Gonzalez Juanatey J R ^a   Alegria E ^b   Zamorano, J L ^b   Bertomeu, V ^b   Velasco, O ^b   Parrondo, I ^b   Honorato, J ^b  

^a University Hospital of Santiago de Compostela   (Spain)

^b Hospital Universitario de Santiago ^*

Author keywords

Albuminuria; Cardiovascular diseases; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AGED; ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 33846944999     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Chobanian AV, Bakris GL, Black HR, Cushman VC, Green LA, Izzo JL y cols.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289: 2560-72, 2003.
2. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-53, 2003.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J y cols.: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24: 1601-10, 2003.
4. American Diabetes Association: Clinical Practice Recommendations 2002. Diabetes Care 25 (Supl. 1): S1-S147, 2002.
5. González-Juanatey JR, Mazón P, Soria F, Barrios V, Rodríguez-Padial L, Bertomeu V. Actualización (2003) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol 56: 487-97, 2003.
6. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 342: 145-53, 2000.
7. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-9, 2000.
8. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB y cols.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-60, 2001.
9. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: the effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-8, 2001.
10. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH y cols., for the RENAAL study investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-9, 2001,
11. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE y cols.: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139: 901-6, 2003.
12. Liu JE, Robbins DC, Palmieri V, Bella JN, Roman MJ, Fabsitz R y cols.: Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study. J Am Coll Cardiol 41: 2022-8, 2003.
13. Verdecchia P, Dovellini EV, Gorini M, Gozzelino G, Lucci D, Milletich A y cols.: Comparison of electrocardiographic criteria for diagnosis of left ventricular hypertrophy in hypertension: the MAVI study. Ital Heart J 1: 207-15, 2000.
14. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 28 (Supl. 1): S37-42, 2005.
15. Marshall SM: Screening for microalbuminuria: which measurement? Diabet Med 8: 706-11, 1991.
16. González-Juanatey JR, Alegría E, García-Acuña JM, González-Maqueda I, Lozano JV: Impacto de la diabetes en las enfermedades cardíacas en España. Estudio Cardiotens 1999. Med Clin (Barc) 116: 686-91, 2001.
17. Palatini P: Microalbuminuria in hypertension. Curr Hypertens Rep 5: 208-14, 2003.
18. MacIsaac RJ, Cooper ME: Microalbuminuria and diabetic cardiovascular disease. Curr Atheroescler Rep 5: 350-7, 2003.
19. Kirpichnikov D, Sowers JR: Role of ACE inhibitors in treating hypertensive diabetic patients. Curr Diab Rep 2: 251-7, 2002.
20. Verhave JC, Hillege HL, Burgerhof JG, Navis G, De Zeeuw D, De Jong PE, for the PREVEND Study Group: Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J Am Soc Nephrol 14: 1330-5, 2003.
21. Diercks GF, Van Boven AJ, Hillege JL, De Jong PE, Rouleau JL, Van Gilst WH: The importance of microalbuminuria as a cardiovascular risk indicator. A review. Can J Cardiol 18: 525-35, 2002.
22. González-Juanatey JR, Alegría E, Lozano JV, Llisterri JL, García-Acuña JM, González-Maqueda I: Impacto de la hipertensión en las cardiopatías en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol 54: 139-49, 2001.
23. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J y cols., for the African American Study of Kidney Disease and Hypertension Study Group: effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 288: 2421-31, 2002.
24. García-Vallejo O, Vicente J, Vegazo O, Jiménez FJ, Llisterri JL, Redón J: Control de la presión arterial de los pacientes diabéticos en el ámbito de atención primaria. Estudio DIAPA, Med Clin (Barc) 120: 529-34, 2003.